The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis O’neal, DN, Kalfas, A, Dunning, Patricia L, Christopher, MJ, Sawyer, SD, Ward, GM and Alford, FP 1994, The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis, Journal of clinical endocrinology and metabolism, vol. 79, no. 4, pp. 975-983, doi: 10.1210/jcem.79.4.7962308. Title The effect of 3 months of recombinant human growth hormone (GH) therapy on insulin and glucose-mediated glucose disposal and insulin secretion in GH-deficient adults: a minimal model analysis Author(s) O’neal, DN Kalfas, A Dunning, Patricia L orcid.org/0000-0002-0284-1706 Christopher, MJ Sawyer, SD Ward, GM Alford, FP Journal name Journal of clinical endocrinology and metabolism Volume number 79 Issue number 4 Start page 975 End page 983 Total pages 9 Publisher Oxford University Press Place of publication Oxford, Eng. Publication date 1994-10-01 ISSN 0021-972X 1945-7197 Keyword(s) human growth hormone (GH) therapy insulin and glucose-mediated glucose disposal insulin secretion Summary The effect of 3 months of low dose (120 μg/kg.week or 0.24 IU/kg.week) recombinant human GH (rhGH) treatment on glucose tolerance, insulin secretion, and insulin- and glucose-mediated glucose disposal was examined in 10 GH-deficient adults. The frequently sampled iv glucose tolerance test was performed at baseline and after 1 week and 3 months of rhGH therapy and analyzed by the minimal model method of Bergman to provide estimates of the glucose decay rate, first and second phase insulin secretion (phi 1 and phi 2), fractional clearance of insulin, and glucose-mediated and insulin-mediated glucose disposal. Fasting glucose, insulin, C-peptide, nonesterified fatty acids (NEFA), and serum cholesterol and triglycerides were also measured. When the 1 week data were compared to baseline, there was a small but significant rise in mean (± SE) fasting glucose (4.62 ± 0.17 vs. 5.1 ± 0.15 mmol/L; P < 0.01), NEFA (0.70 ± 0.09 vs. 1.1 ± 0.12 mmol/L; P < 0.005), insulin (93.6 ± 8.9 vs. 238.9 ± 9.2 pmol/L; P < 0.0001), C-peptide (0.32 ± 0.13 vs. 0.66 ± 0.13 nmol/L; P < 0.005), and phi 1 (11.9 ± 1.3 vs. 16.2 ± 1.8 pmol/L.min/mmol.L x 10(2)) and phi 2 (1.43 ± 0.17 vs. 3.15 ± 0.25 pmol/L.min/mmol.L x 10(3); P < 0.05). Conversely, there were associated decreases in glucose decay rate (1.83 ± 0.26 vs. 1.28 ± 0.12 min-1; P < 0.05) and insulin-mediated glucose disposal (0.36 ± 0.08 vs. 0.18 ± 0.06 min/pmol.L x 10(-4); P < 0.005). There was no change in glucose-mediated glucose disposal or the fractional clearance of insulin. By 3 months, fasting insulin and C-peptide levels remained significantly elevated, whereas other parameters had returned to baseline. There was a minor reduction in serum cholesterol at 1 week (5.1 ± 0.15 vs. 4.62 ± 0.17 mmol/L; P < 0.01), which was not maintained at 3 months. Serum triglycerides remained unchanged throughout the study. We conclude that short term low dose rhGH treatment of GH-deficient adults induces a temporary state of mild glucose intolerance, hyperinsulinemia, insulin resistance, and raised NEFA levels at 1 week. By 3 months, these metabolic disturbances had returned to baseline for a persisting modest hyperinsulinemia. Whether this hyperinsulinemia will last over the longer term and/or has distant detrimental metabolic consequences in the individual must await further studies. Language eng DOI 10.1210/jcem.79.4.7962308 Indigenous content off Field of Research 1103 Clinical Sciences 1114 Paediatrics and Reproductive Medicine HERDC Research category C1.1 Refereed article in a scholarly journal Copyright notice ©1994, The Endocrine Society Persistent URL http://hdl.handle.net/10536/DRO/DU:30127205 Document type: Journal Article Collections: Faculty of Health School of Nursing and Midwifery Related Links Link Description   Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved. Versions Version Filter Type Thu, 18 Jul 2019, 15:46:50 EST Fri, 19 Jul 2019, 05:11:33 EST Fri, 19 Jul 2019, 06:12:23 EST Thu, 22 Aug 2019, 14:03:08 EST Thu, 22 Aug 2019, 14:04:28 EST Filtered Full Citation counts:   Cited 0 times in TR Web of Science Cited 105 times in Scopus Search Google Scholar Access Statistics: 123 Abstract Views  -  Detailed Statistics Created: Thu, 18 Jul 2019, 15:46:50 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.